Long-term outcomes of rituximab therapy in pemphigus.
Iakov ShimanovichT BaumannE SchmidtD ZillikensC M HammersPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Lower desmoglein-specific antibody levels at baseline were predictive of CRoff. In patients receiving multiple rituximab cycles, complete remission after the first cycle was associated with a favourable long-term outcome. Repeated rituximab courses were highly effective for relapsed disease and improved the overall outcome.